ObsEva SA

OTCPK:OBSE.F Lagerbericht

Marktkapitalisierung: US$11.7k

ObsEva Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Es liegen keine ausreichenden Daten über die Leistung von ObsEva in den letzten Jahren vor.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Wachstum der Industrie17.04%
Wachstumsrate der Einnahmenn/a
Eigenkapitalrenditen/a
Netto-Margen/a
Letzte Ertragsaktualisierung30 Jun 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Seeking Alpha • Aug 22

ObsEva stock dips on Nasdaq non-compliance notice

ObsEva SA (NASDAQ:OBSV) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholders' equity of ~$2.10M. ObsEva has until Aug. 29 to submit a plan to regain compliance after Nasdaq decided to provide a shortened response time to the company. The company said it intends to submit plan by the date. On July 27, ObsEva stock fell ~78% on plans to restructure following setback for uterine fibroids drug. Earlier in August, the company said it was retiring $31M in debt and had announced $11M debt refinancing. OBSV -4.13% to $0.23 premarket Aug. 22
Seeking Alpha • Aug 01

ObsEva to retire $31M in debt and announces $11M debt refinancing

ObsEva (NASDAQ:OBSV) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. Under agreement terms, ObsEva and JGB agreed to apply the $31M cash earlier held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a 25% prepayment penalty on the early debt retirement. JGB has agreed to forbear for a period of up to three months from enforcing any rights or remedies under the notes. In exchange, $1.5M was added to the outstanding principal balance under the notes, leading to ~$11M of convertible notes outstanding, and the conversion price of the notes was adjusted to a conversion price of $0.26/share. Shares trading 1.6% higher premarket.
Seeking Alpha • Jul 05

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for the treatment of women with uterine fibroids set for September 13, 2022. Trial results from the phase 3 EDELWEISS 3 study and long-term extension study for endometriosis are expected 2nd half of 2022; Post-treatment follow-up results from extension study expected early 2023. ObsEva SA (OBSV) is a great long-term biotech to own. The reason why I state that is because despite having received regulatory approval in two territories for linzagolix (marketed as Yselty) for the treatment of women with uterine fibroids, the stock still trades at a very low share price. It received approval of this drug for the treatment of this patient population for the European Union and for the United Kingdom. I believe there is long-term potential just based on these approvals. However, there is an ability to further expand the reach of Yselty to the United States. That's because there is a PDUFA date set for September 13, 2022, and that is when the FDA will decide if this drug should be approved for the very same patient population for use in the United States. I believe that the FDA approval may carry more weight compared to the other two regulatory approvals. Not only that, but the biotech won't have to attempt to sell the drug on its own. Instead, it has already been able to establish two partners for specific territories. It established a partnership for Theramex to sell the drug outside of the U.S., Canada, and Asia. The other partnership that was established was with Syneos Health to sell the drug within the United States upon regulatory approval. It is developing Yselty (linzagolix) for another large market indication which is endometriosis as well. With a few regulatory approvals for Yselty, plus another possible one on the way in Q3 of 2022, these are the reasons why I believe that ObsEva is a great long-term biotech to look into. Two Regulatory Approvals With A Third One Being Possible As I noted directly above, ObsEva received regulatory approvals of Yselty for the treatment of women with uterine fibroids in two territories. Uterine fibroids are benign tumors that end up forming in the uterus (womb) of a woman. When I state the term "benign," that means non-cancerous. The thing is that a majority of the time there are no symptoms. However, in certain cases, they can cause severe pain for the patient. There are several symptoms that uterine fibroids can cause, which are: Heavy Menstrual bleeding Prolonged periods Pelvic pain Cramping Urge to urinate One immediate item to point out is that Yselty was explored in uterine fibroid patients with heavy menstrual bleeding. Thus, heavy menstrual bleeding ((HMB)) is one of the symptoms involved with this disease. Some ways to treat this disease are surgeries and medications. Surgeries may involve attempting to go in and remove the uterine fibroids if successful. The other option involves medications. There are two types of medications: SERMs (Selective estrogen receptor modulators) - work by changing estrogen levels in the body and holds the ability to shrink fibroids without causing menopause symptoms GnRH agonist - GnRH is a type of hormone that a person's body makes naturally. These agonist drugs act as a counter to the production of the GnRH hormone. Thus, in turn it is able to shrink fibroids and sometimes can even reduce anemia as well There are many other additional types of surgeries as well, like cutting off the blood supply to kill the fibroid off. The thing is that the uterine fibroids market is a large one. Well, it only treats women and it is just benign fibroids that are being formed in the uterus. Yes, but believe it or not it is indeed a major problem. Just in the United States alone, it is expected that the uterine fibroids treatment market is estimated to be worth $298.5 million by the end of 2027. One of the first regulatory approvals was achieved back on June 22, 2022, from the European Commission ((EC)). This approval was followed by a positive opinion from the Committee Medicinal Products for Human Use of the European Medicines Agency back in April of 2022. Then, the biotech was able to receive UK Medicines and Healthcare Products Regulatory Agency ((MHRA)) approval of Yselty for this very same patient population. The reason why Yselty was approved was because of positive results from the two phase 3 PRIMROSE studies that were done. It was noted from 24 weeks that there were huge response rates. The breakdown of such response rates is as follows: A responder rate of 84.5% in women who received 200 mg linzagolix with hormonal add back therapy ((ABT)) A responder rate of 56.5% in women who received 100 mg of linzagolix without ABT These two response rates, plus safety profile of the drug, is what allowed for these regulatory approvals. However, where I believe ObsEva may have a competitive advantage is that Yselty is the first drug approved for this specific patient population that gives women the option to be treated without the need for hormone therapy. The need for a drug like Yselty now is to help a woman either delay or avoid the need for surgery altogether. There is potential to expand regulatory approval of Yselty to the United States with the upcoming FDA decision in the 2nd half of 2022. A Prescription Drug User Fee Act ((PDUFA)) date has been established with an action date of September 13, 2022. Agreement has been made in partnership with Theramex to sell Yselty outside of the U.S., Canada and Asia. Another agreement had been made with Syneos Health to sell the drug in the United States upon regulatory approval. Financials According to the 6-K SEC Filing, ObsEva had cash and cash equivalents of $57.6 million as of March 31, 2022. It has been able to raise cash through several different methods over the years. It raised about $5.7 million of net cash in Q1 of 2022 using its at-the-market offering program. Then, made $8.3 million in proceeds from its securities purchase agreement with JGB Management. Speaking of which, this JGB Securities Purchase Agreement is structured to provide about $135 million in borrowing capacity in nine tranches. The first and second tranche were achieved, October 2021 and then January 2022 respectively.

Aufschlüsselung der Einnahmen und Ausgaben

Wie ObsEva Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OTCPK:OBSE.F Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 2320815-11
31 Mar 2320-2120-5
31 Dec 2220-30250
30 Sep 224-772525
30 Jun 2222-5832-17
31 Mar 220-502543
31 Dec 2122-53250
30 Sep 210-571856
30 Jun 210-821465
31 Mar 210-811366
31 Dec 200-831268
30 Sep 200-851270
30 Jun 200-881472
31 Mar 200-1051885
31 Dec 190-1091988
30 Sep 190-1082086
30 Jun 190-991980
31 Mar 190-831667
31 Dec 180-771463
30 Sep 180-741361
30 Jun 180-721359
31 Mar 180-711358
31 Dec 170-671355
30 Sep 170-611349
30 Jun 170-521241
31 Mar 170-41933
31 Dec 160-30624
30 Sep 160-26520
30 Jun 160-21318
31 Mar 160-20316
31 Dec 150-20317

Qualität der Erträge: Unzureichende Daten, um festzustellen, ob OBSE.F hohe Ertragsqualität hat.

Wachsende Gewinnspanne: Es liegen keine ausreichenden Daten vor, um festzustellen, ob sich die Gewinnspannen von OBSE.F im letzten Jahr verbessert haben.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die jährliche Gewinnwachstumsrate von OBSE.F in den letzten 5 Jahren positiv war.

Beschleunigtes Wachstum: Unzureichende Daten, um das Gewinnwachstum des vergangenen Jahres mit dem 5-Jahres-Durchschnitt von OBSE.F zu vergleichen.

Erträge im Vergleich zur Industrie: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Gewinnwachstum von OBSE.F im vergangenen Jahr über dem Branchendurchschnitt von Biotechs lag.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: OBSE.F hat eine negative Eigenkapitalrendite (0%), da es derzeit unrentabel ist.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 18:37
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

ObsEva SA wird von 9 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Nathan WeinsteinAegis Capital Corporation
Mayur SomaiyaBMO Capital Markets Equity Research
Edward NashCanaccord Genuity